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Contraction of bladder smoothmuscle is predominantly initiated byM3 muscarinic receptor-
mediated activation of the Gq/11-phospholipase C β-protein kinase C (PKC) and the G12/13-
RhoGEF-Rho kinase (ROCK) pathways. However, these pathways and their downstream
effectors are not well understood in bladder smooth muscle. We used phorbol 12,13-
dibutyrate (PDBu), and 1,2-dioctanoyl-sn-glycerol (DOG), activators of PKC, in this inves-
tigation. We were interested in dissecting the role(s) of PKC and to clarify the signaling
pathways in bladder smooth muscle contraction, especially the potential cross-talk with
ROCK and their downstream effectors in regulating myosin light chain phosphatase activity
and force.To achieve this goal, the study was performed in the presence or absence of the
PKC inhibitor bisindolylmaleimide-1 (Bis) or the ROCK inhibitor H-1152. Phosphorylation
levels ofThr38-CPI-17 andThr696/Thr850 myosin phosphatase target subunit (MYPT1) were
measured during PDBu or DOG stimulation using site speciﬁc antibodies. PDBu-induced
contraction in bladder smooth muscle involved both activation of PKC and PKC-dependent
activation of ROCK. CPI-17 as a major downstream effector, is phosphorylated by PKC
and ROCK during PDBu and DOG stimulation. Our results suggest that Thr696 and Thr850-
MYPT1 phosphorylation are not involved in the regulation of a PDBu-induced contraction.
The results also demonstrate that bladder smooth muscle contains a constitutively active
isoform of ROCK that may play an important role in the regulation of bladder smooth mus-
cle basal tone.Together with the results from our previous study, we developed a working
model to describe the complex signaling pathways that regulate contraction of bladder
smooth muscle.
Keywords: MLC phosphatase, myosin phosphatase target subunit, CPI-17, bisindolylmaleimide-1, H-1152, MLC
phosphorylation
INTRODUCTION
It is well accepted that phosphorylation of the 20-kDa regula-
tory myosin light chain (MLC), catalyzed by the Ca2+/calmodulin
dependent MLC kinase and dephosphorylation catalyzed by the
MLC phosphatase, play a primary role in the regulation of smooth
muscle contraction and relaxation (Sobieszek, 1977; for reviews
see Kamm and Stull, 1985; Somlyo and Somlyo, 1994). In addi-
tion, agonist stimulation of G-protein coupled receptors increases
contraction in smooth muscle by both activating the MLC kinase
and inhibiting the MLC phosphatase (Kimura et al., 1996; Som-
lyo and Somlyo, 2003), the result of which is an increase in MLC
phosphorylation levels to values greater than those achieved by
the simple activation of the MLC kinase alone. Inhibition of the
MLC phosphatase can result from either protein kinase C (PKC)-
catalyzed phosphorylation of CPI-17 or Rho kinase (ROCK)-
catalyzed phosphorylation of the myosin phosphatase target sub-
unit (MYPT1). Bothpathways play key roles in the enhancement of
myoﬁlament Ca2+ sensitivity (Eto et al., 1995, 2004; Hartshorne,
1998; Kitazawa et al., 2000; Somlyo and Somlyo, 2003). These
signaling pathways have been extensively studied in vascular and
some non-vascular smooth muscle (Eto et al., 1997; Feng et al.,
1999). However, studies in bladder smooth muscle are not as
numerous and therefore our understanding of the mechanisms
underlying Ca2+ sensitization in bladder is signiﬁcantly less.
Contraction of bladder smooth muscle during voiding is pre-
dominantly initiated by acetylcholine activation of M3 muscarinic
receptors (Frazier et al., 2008). We used carbachol in a previous
study to initiate contraction of bladder smooth muscle with the
goal of studying the potential role(s) of PKC and ROCK path-
ways in an agonist-induced contraction (Wang et al., 2009). Our
results demonstrated that phosphorylation of both CPI-17 and
MYPT1, effectors of the PKC and ROCKpathways respectively, are
involved in the regulation of carbachol-dependent bladder smooth
muscle contraction (Wang et al., 2009). It is unclear, however,what
role(s) PKC and ROCK play in the phosphorylation of CPI-17 and
MYPT1 andwhether or not there is any cross-talk between the two
pathways during bladder smooth muscle contraction as has been
suggested in other smooth muscles (Niiro et al., 2003). For exam-
ple, activation of ROCK by PKC, speciﬁcally the PKCδ isoform,
has been shown to be involved in several cell functions, including
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vascular smooth muscle migration and contraction (Kandabashi
et al., 2003; Ohtsu et al., 2005; Poole and Furness, 2007).
The ﬁrst goal of this study was to more clearly deﬁne the
role(s) of PKC and ROCK in bladder smooth muscle contrac-
tion and test the hypothesis that both PKC and ROCK regulate
contraction through phosphorylation of CPI-17. We were also
interested in testing the speciﬁc hypothesis that in addition to
direct phosphorylation of CPI-17, activation of PKC also increases
ROCK activity resulting in an increase in CPI-17 phosphoryla-
tion. To test this hypothesis, we used phorbol 12,13-dibutyrate
(PDBu), 1,2-dioctanoyl-sn-glycerol (DOG) an analog of the more
physiologically relevant diacylglycerol (DAG), and the inactive iso-
mer of PDBu, 4α-phorbol 12,13-dibutyrate (α-PDBu). Using this
approach we could, with some assurance, speciﬁcally activate only
the PKC pathway (Castagna et al., 1982). Therefore any effect of
PDBu or DOG on ROCK activity would be through activation of
PKC. The second goal of this study was to build upon our earlier
report (Wang et al., 2009) to dissect the effect(s) of PKC activation
directly via PDBu or DOG from both PKC and ROCK activation
via carbachol stimulation. This will then allow us to develop a
working hypothesis to help guide future studies on both the nor-
mal physiological regulation of bladder smooth muscle and the
altered regulation that may occur in pathophysiological states.
MATERIALS AND METHODS
INTACT BLADDER SMOOTH MUSCLE PREPARATION
Male New Zealand White rabbits weighing 2–2.5 kg were used in
this study. All animal studies and procedures were approved by the
Drexel University College of Medicine’s Institutional Animal Care
and Use Committee. Rabbits were euthanized by a pentobarbital
overdose administered via the ear vein followed by exsanguina-
tion. The bladders were then quickly removed and placed in ice
cold physiological salt solution (MOPS-buffered PSS). MOPS-
buffered PSS contained (in mM) 140 NaCl, 4.7 KCl, 1.2 MgSO4,
1.6 CaCl2, 1.2 Na2HPO4, 2 MOPS (pH 7.4), 5 d-glucose, and
0.02 EDTA. The bladder neck, trigone, and base regions were
removed, leaving only the middle detrusor body for experimen-
tation. The detrusor body was dissected in cold MOPS-buffered
PSS under a dissecting microscope. The mucosal and serosal lay-
ers were carefully removed and strips containing primarily smooth
muscle (∼1.5mm× 6mm) were cut along the central axis of the
bladder in the longitudinal orientation as previously described (Su
et al., 2003) and stored in MOPS-buffered PSS at 4˚C until used.
Our bladder strips, devoid of serosal and mucosal layers and are
predominately smoothmuscle, do not typically show spontaneous
activity such as those preparations containing urothelial and other
modulatory cells (Su et al., 2003; Stanton et al., 2006). Storage was
never longer than 24 h and storage had no effect on the presence or
absence of spontaneous activity or magnitude of contractile force.
ISOMETRIC FORCE RECORDING
The bladder strips were mounted between a Grass FT.03 force
transducer and a stationary clip in water-jacketed muscle organ
baths containing MOPS-buffered PSS at 37˚C and aerated with
100% O2. The strips were stretched and allowed to stress–relax
until a passive force of ∼1 g was achieved. This passive force
approximates the optimal length for maximal active stress devel-
opment (Lo; Su et al., 2003; Wang et al., 2009). The strips were
then allowed to equilibrate for at least 40min until a stable basal
force recording was obtained.
After the equilibration period, strips were stimulated with
110mM KCl–MOPS-buffered PSS (equal-molar substitution of
KCl for NaCl) then relaxed with MOPS-buffered PSS; this
contraction–relaxation cycle was repeated four times. One hun-
dred ten millimolar KCl–MOPS-buffered PSS was used as the
stimulus to decrease diffusion time of the depolarizing K+ into
the tissue, thus decreasing the delay from addition of the stimulus
to initiation of contraction, and therefore increase the time to peak
contraction as is standard procedure in our laboratory (Moreland
and Moreland, 1987; Fulginiti et al., 1993; Gorenne et al., 1998;
Su et al., 2003, 2004; Stanton et al., 2006). The peak force in each
equilibrated muscle strip was used to normalize the force gener-
ated with PDBu, α-PDBu, or DOG stimulation. A concentration
response curve was generated in response to DOG, demonstrat-
ing that 300μMproduced a maximal response. Data therefore are
presented as a percentage of themaximal response to 110mMKCl.
Bisindolylmaleimide-1 (Bis, 3μM) andH-1152 (1μM)were used
to inhibit PKC (Toullec et al., 1991) and ROCK (Sasaki et al., 2002)
activity, respectively. Bis and H-1152 concentrations were chosen
based on published and unpublished studies from our lab (Stan-
ton et al., 2006; Wang et al., 2009). We previously used 10μM Bis
to inhibit PKC activity, however recent preliminary studies have
shown that 3μM Bis inhibited PDBu-induced contractions but
not Ca2+-dependent contractions of Triton X-100 skinned blad-
der smooth muscle strips suggesting that this concentration of Bis
has nonon-signiﬁcant effects on theMLCkinase (data not shown).
The inhibitors were added to the muscle bath 20min prior to the
addition of stimulus. Tissues were allowed to contract for 5min
and then relaxed by rinsing with MOPS-buffered PSS.
In studies to examine the calcium-dependence of PDBu-
induced contractions we used procedures previously published
by our laboratory (Su et al., 2004). To examine the dependence
on extracellular calcium, tissues were incubated in calcium-free
MOPS-buffered PSS for 15min followed by stimulation with
PDBu. To examine the PDBu response in the absence of both
extracellular and intracellular calcium, the tissues were bathed
in MOPS-buffered PSS containing 0.1mM EGTA and then con-
tracted by the addition of 10μM carbachol for 7min to release
and chelate intracellular calcium. The tissues were then rinsed in
calcium-free MOPS-buffered PSS and subjected to a second car-
bachol stimulation to ensure removal of intracellular calcium. Tis-
sues were then rinsed and bathed in calcium-free MOPS-buffered
PSSwithout EGTA for 15min followed by stimulationwith PDBu.
All muscle strips were stimulated with carbachol at the end of each
experiment to ensure the procedures to alter calcium source(s) did
not affect tissue viability.
MEASUREMENT OF MLC PHOSPHORYLATION
Myosin light chain phosphorylation levels were measured by stan-
dard techniques previously published by our laboratory (More-
land and Moreland, 1987; Moreland et al., 1992; Su et al., 2004;
Wang et al., 2009). Brieﬂy, strips were rapidly frozen in a dry
ice/acetone slurry containing 6% trichloroacetic acid and 10mM
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DTT at various time points (0, 1.5, 3, and 5min) of PDBu
stimulation. The strips were then slowly thawed to room tem-
perature, rinsed in acetone, air dried, and subjected to homoge-
nization in a 1% SDS, 10% glycerol, and 1mMDTT solution using
glass/glass homogenizers. Samples were centrifuged at 12,000 rpm
for 6min and subjected to two-dimensional gel electrophoresis
and transferred to nitrocellulose membranes for quantiﬁcation of
MLC phosphorylation as previously described (Moreland et al.,
1992). Transferred proteins were visualized with Colloidal Gold
Stain (Amersham Biosciences, Piscataway, NJ, USA) and digitized
by densitometric analysis using a Bio-Rad GS-800 quantitative
densitometer (Bio-Rad, Hercules, CA, USA). MLC phosphoryla-
tion levels were calculated by dividing the densitometric analysis of
the spot corresponding to the phosphorylated MLC by the sum of
the densitometric analyses of the spots corresponding to the phos-
phorylated and unphosphorylated MLC. Values are presented as
mole P i/mole MLC.
QUANTIFICATION OF CPI-17 PHOSPHORYLATION
Tissue strips, resting or stimulated, were rapidly frozen and then
processed as previously described (Wang et al., 2009). For studies
comparing phosphorylation in response to PDBu in the pres-
ence or absence of PKC or ROCK inhibitors the membranes were
blocked with 5% bovine serum albumin (BSA, Sigma-Aldrich Inc,
St. Louis,MO,USA) in a phosphate buffered saline (PBS) solution
for 1 h, and incubated with an antibody against Thr38-phospho-
CPI-17 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight at 4˚C. The membranes were brieﬂy rinsed with double
deionized water and incubated with a polyclonal goat anti-rabbit
antibody conjugated to horseradish peroxidase (1:5,000; Upstate
Cell Signaling, Billerica, MA, USA). Immunoreactive bands were
detected using enhanced chemiluminescence (ECL, Amersham
Biosciences, Piscataway, NJ, USA). The blots were stripped and re-
probedusing aprimary antibody against totalCPI-17 (1:400; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) followed by washes in
a PBS-0.05% Tween-20 solution. The washed membranes were
incubated with a monoclonal sheep anti-mouse antibody conju-
gated to horseradish peroxidase (1:10,000;AmershamBiosciences,
Piscataway, NJ, USA).
For studies comparing CPI-17 phosphorylation in response to
PDBu to that in response to α-PDBu or DOG stimulation, mem-
branes were incubated with an antibody against Thr38-phospho-
CPI-17 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and an antibody against CPI-17 (1:400; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) overnight at 4˚C. Membranes were washed
in a PBS-0.1% Tween-20 solution and incubated with a goat anti-
mouse IRDye 800cw conjugated secondary antibody and a goat
anti-rabbit IRDye 680cw conjugated polyclonal secondary anti-
body for 45min at room temperature (1:10,000 goat anti-rabbit,
1:10,000 goat anti-mouse, Li-Cor Biosciences, Lincoln, NE, USA)
then washed in 0.1% Tween-PBS. Protein was visualized with the
Li-Cor Odyssey Infrared Imaging System.
The ratio of the density of the band corresponding to the
Thr38-phospho-CPI-17 to that of the band corresponding to total
CPI-17 was used to determine CPI-17 phosphorylation levels in
response to PDBu in the presence or absence of inhibitors of
PKC or ROCK. For blots quantiﬁed using the Odyssey imager
all ratios of phosphorylated to unphosphorylated proteins were
compared to the ratio in resting tissues, which was set at 100%.
In most experiments protein loadings were similar, but for all
measurements a direct comparison of the levels of phosphory-
lated protein to total protein were obtained in the same blot by
stripping and re-probing as previously demonstrated (Gorenne
et al., 1998). When utilizing the Odyssey imager, phosphorylated
and total protein levels were measured on the same blot. Any blot
demonstrating saturated spots was not used in the analyses. We
have previously shown that this probe, stripping, and re-probing
protocol accurately quantiﬁes phosphoprotein levels that are lin-
early related to kinase phosphotransferase activity (Gorenne et al.,
1998).
QUANTIFICATION OF MYPT1 PHOSPHORYLATION
Tissue strips, resting or stimulated, were rapidly frozen and then
homogenized in a buffer including a Protease Inhibitor Cock-
tail solution (1:100; Sigma-Aldrich Inc, St. Louis, MO, USA), as
described above. The samples were subjected to electrophoresis
in a 7.5% SDS-acrylamide gel and transferred onto a nitrocellu-
lose membrane. The membranes were blocked with 3% non-fat
dry milk in a PBS solution for 40min and incubated with a pri-
mary antibody against either Thr696 or Thr850 phospho-MYPT1
(1:2,000 Upstate Cell Signaling, Billerica, MA, USA) overnight at
4˚C. The membranes were brieﬂy washed with double deionized
water and incubated with a polyclonal goat anti-rabbit antibody
conjugated to horseradish peroxidase (1:5,000; Upstate Cell Sig-
naling, Billerica,MA,USA). Immunoreactive bands were detected
using ECL (Amersham Biosciences, Piscataway, NJ, USA). The
blots were stripped and re-probed using a primary MYPT1 anti-
body (1:10,000; Covance Inc, Princeton, NJ, USA) followed by
washes in a PBS-0.05% Tween-20 solution and then incubated
with a polyclonal goat anti-rabbit antibody conjugated to horse-
radish peroxidase (1:5,000; Upstate Cell Signaling, Billerica, MA,
USA).
For studies comparing phosphorylation in response to PDBu
stimulation to that in response to α-PDBu or DOG, membranes
were blocked for 1 h in Odyssey Blocking Buffer (Li-Cor Bio-
sciences) and incubated in primary antibody as described above.
Membraneswerewashed in PBS-0.1%Tween-20 followed by incu-
bation with goat anti-rabbit IRDye 680cw conjugated polyclonal
secondary antibody for 45min at room temperature (1:10,000 goat
anti-rabbit, Li-Cor Biosciences, Lincoln, NE, USA) and washed
with 0.1% Tween-PBS. The membranes were visualized using the
Li-Cor Odyssey Infrared Imaging System. The blots were stripped
in NewBlot Nitro Stripping Buffer (Li-Cor Biosciences, Lincoln,
NE, USA) for 10min, washed in PBS for 5min, and re-probed
using a primaryMYPT1 antibody (1:10,000; Covance Inc., Prince-
ton, NJ, USA) followed by the same washes, secondary antibody
incubation, and visualization as described above.
The ratio of thedensity of thebands corresponding tophospho-
Thr696 or phospho-Thr850 to the bands corresponding to total
MYPT1 was used to determine MYPT1 phosphorylation levels.
For blots quantiﬁed using the Odyssey imager all ratios of phos-
phorylated to total protein were compared to the same ratio in
unstimulated tissues, which was set at 100%. In most experiments
protein loadingswere similar,but in all blots a direct comparisonof
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phosphorylated protein levels to total protein levels was obtained
in the same blot by stripping and re-probing.
MATERIALS AND STATISTICS
All reagents, unless otherwise speciﬁed below, were purchased
from Fisher Scientiﬁc (Pittsburgh, PA, USA) and were of analyti-
cal grade or better. All electrophoretic and blotting reagents were
obtained from Bio-Rad Laboratories (Hercules, CA, USA) and
Li-Cor Biosciences (Lincoln, NE, USA). Bis and H-1152 were pur-
chased from Calbiochem (San Diego, CA, USA). Phorbol 12,13-
dibutyrate was purchased from Sigma-Aldrich (St. Louis, MO,
USA). DOG and α-PDBu were purchased from Enzo Life Sciences
(PlymouthMeeting, PA,USA) and dissolved in dimethyl sulfoxide
(DMSO). Unless otherwise noted, membrane antibody stripping
solutions were purchased from Pierce Biotechnology (Rockford,
IL, USA).
Statistical signiﬁcance between means was determined using
one-way ANOVA followed by the Tukey post hoc test. A P
value< 0.05 was taken as signiﬁcant. All “n” values refer to the
number of bladder muscle strips; each strip was taken from a
different animal.
RESULTS
ISOMETRIC FORCE IN RESPONSE TO PDBu, α-PDBu, OR DOG
STIMULATION
The addition of PDBu results in a dose dependent contraction of
bladder smooth muscle (Yoshida et al., 1992; Stanton et al., 2006;
Chang et al., 2009). Threemillimolar PDBuwas used in the present
study to induce a maximal PDBu-dependent contraction in rabbit
bladder smooth muscle. Representative tracings of a contraction
in response to PDBu alone or in the presence of 3μMBis or 1μM
H-1152 are shown in Figure 1A. Several such experiments were
averaged and are shown in Figure 1B. As shown in Figure 1B,
PDBu-dependent isometric force was measured at 0, 1.5, 3, and
5min of stimulation and expressed as a percentage of the strips’
maximal response to 110mM KCl. Maximal stress in response to
110mM KCl in our preparation of bladder smooth muscle aver-
ages 6.8± 0.4× 104 N/m2. Force levels earlier than 1.5min were
lower than those measured at 1.5–3min. Smooth muscle strips
produced a slowly developing contraction in response to PDBu.
Peak force was attained at∼1.5min of contraction with a value of
36.5± 2.2% of the maximal force in response to KCl stimulation.
The sustained portion of the PDBu-dependent contraction began
FIGURE 1 | PDBu, α-PDBu, or DOG-stimulated bladder smooth muscle
contraction and the effects of PKC or ROCK inhibition or calcium
removal. (A) Representative tracing of contractions in response to 3μM
PDBu alone (top tracing), and in the presence of 3μM Bis (middle tracing), or
1μM H-1152. Arrow denotes the addition of PDBu, inhibitors were added
20min prior to stimulation. (B) Intact strips of bladder smooth muscle were
contracted for 5min with PDBu (3μM) in the presence or absence of Bis
(3μM) or H-1152 (1μM). Strips contracted in response to PDBu alone (•)
generated 36.5+2.2% of maximal force at ∼1.5min and maintained a
sustained contraction until ∼3min. Inhibition with Bis () or H-1152 ()
signiﬁcantly decreased force at 1.5 and 3min. H-1152 also signiﬁcantly
decreased basal force at 0min. Stimulation with α-PDBu () did not elicit an
increase in force until 5min. (C) Intact strips of bladder smooth muscle were
contracted for 10min with DOG (300μM). DOG (•) generated force
signiﬁcantly greater than basal values at 2.5 and 5min of stimulation, but not
signiﬁcantly different from basal values at 10min. Vehicle alone (DMSO, )
had no effect. (D) Intact strips of bladder smooth muscle were contracted for
5min with PDBu (3μM, •) in the presence or absence of extracellular calcium
or after depletion of all calcium stores. Strips contracted in the absence of
extracellular calcium () or following the depletion of all calcium stores () did
not respond to PDBu. Values shown are the means±SE of at least ﬁve
determinations. *P <0.05, compared with values in the presence of PDBu
alone (B), DMSO alone (C), or the absence of calcium (D). #P <0.05,
compared with values at 0min of the same treatment.
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to decrease at approximately 3min and returned to values not
signiﬁcantly different from baseline by 5min of continued stimu-
lation. The addition of α-PDBu, the inactive isomer of PDBu, did
not result in contraction of bladder smooth muscle (Figure 1B).
Three millimolar α-PDBu was used in the present study to pro-
vide a direct comparison to the same concentration of the active
phorbol ester, PDBu. Pre-incubation with the PKC inhibitor Bis
abolished the PDBu-induced contraction. Pre-incubation with
the ROCK inhibitor H-1152 signiﬁcantly decreased the PDBu-
stimulated contraction as well as decreased basal resting tone of
the tissue (Figure 1B). The inhibition of PDBu-stimulated force
in response to H-1152 was signiﬁcantly less than that produced
by Bis at 1.5 and 3min of stimulation. These results suggest that
PKC is responsible for the PDBu-dependent contraction; however,
there also appears to be a signiﬁcant role for ROCK activation as
evidenced by the loss of developed force in the presence of H-1152.
The addition of DOG (300μM) resulted in an increase in
isometric force in bladder smooth muscle. Preliminary studies
demonstrated that 300μM DOG produced a maximal contractile
response. As shown in Figure 1C, isometric force was measured
at 0, 2.5, 5, and 10min of stimulation and was expressed as a per-
centage of the maximal response to 110mM KCl. Smooth muscle
strips developed a slow contraction in response to DOG quali-
tatively similar to that seen with PDBu. Peak force was attained
at ∼2.5min of stimulation with a value of 23.1± 1.6% of max-
imal force in response to KCl stimulation and did not return to
basal values until 10min of stimulation. The slower onset of con-
traction in response to DOG as compared to PDBu is most likely
due to slower diffusion rate of DOG through the interstitial space
and membrane lipid bilayer. The more rapid decline in force in
response to DOG as compared to PDBu is most likely due to the
fact thatDOGishydrolyzed,albeitmore slowly thandiacylglycerol.
The vehicle, DMSO, alone had no effect on force.
Bladder smooth muscle strips were subjected to PDBu stim-
ulation after removal of extracellular calcium or removal of all
sources of calcium. As shown in Figure 1D, removal of either
extracellular calcium or all calcium sources abolished contraction
in response to PDBu stimulation. These data suggest that PDBu-
induced contractions of bladder smooth muscle are extracellular
calcium-dependent.
MYOSIN LIGHT CHAIN PHOSPHORYLATION IN RESPONSE TO PDBu
STIMULATION
Themechanism(s) by which PDBu induces contraction of bladder
smoothmuscle is assumed to be due to the activation of PKC. Our
demonstration that DOG produces a contraction similar to PDBu
supports this assumption. However, the regulatory steps that are
involved beyond activation of PKC are not well deﬁned. In fact the
published evidence is not consistentwith regards towhether or not
MLC phosphorylation is involved in a PDBu-induced contraction
(Rembold and Murphy, 1988; Fulginiti et al., 1993; Stanton et al.,
2006). In our present study, we addressed this issue by measuring
MLC phosphorylation levels in response to PDBu stimulation, in
the presence or absence of PKC or ROCK inhibitors. As shown in
Figure 2A, stimulation of bladder smoothmuscle strips with 3μM
PDBu increasedMLCphosphorylation levels with a temporal pro-
ﬁle similar to that of force generation in response to PDBu alone; a
FIGURE 2 | PDBu-stimulated MLC phosphorylation levels in bladder
smooth muscle. Intact strips of bladder smooth muscle were contracted
for 5min with PDBu (3μM) in the presence or absence of Bis (3μM) or
H-1152 (1μM). Strips were rapidly frozen at 0, 1.5, 3, and 5min of
contraction and then processed for quantiﬁcation of MLC phosphorylation
levels. (A) PDBu stimulation signiﬁcantly increased MLC phosphorylation
levels at 1.5 and 3min (•). MLC phosphorylation levels in strips incubated
with either Bis (o) or H-1152 () prior to PDBu stimulation were not
signiﬁcantly greater than basal values. (B) Percent increase in MLC
phosphorylation levels from basal values in response to PDBu alone (•) or
after 20min incubation in Bis (o) or H-1152 (). Values shown are the
means±SE of 8–10 determinations. #P <0.05, as compared with values at
0min of the same treatment. *P <0.05, as compared to PDBu alone at the
same time point.
slow increase followedby adecline to basal values (see force proﬁles
in Figures 1A,B). Considering that maximal PDBu-induced force
is approximately 36% of that produced in response to 110mM
KCl, the relatively small increase in MLC phosphorylation levels is
not surprising. Pre-incubation with the PKC inhibitor Bis reduced
MLC phosphorylation levels, but the reduction only reached lev-
els of signiﬁcance at 3min of PDBu stimulation as compared to
PDBu-stimulated alone. Similar to PDBu-inducedMLCphospho-
rylation levels at most time points in the presence of Bis, H-1152
also depressed MLC phosphorylation levels, albeit not statistically
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signiﬁcant. Interestingly, Bis and H-1152 signiﬁcantly reduced or
abolished PDBu-induced force while the effects on MLC phos-
phorylation were minimal. In order to determine if a change in
basal values of MLC phosphorylation resulting from inhibition
of PKC or ROCK affected PDBu-induced increases, we calculated
the percent increase in MLC phosphorylation from basal. These
calculations are shown in Figure 2B. Although no values were
statistically signiﬁcant due to the variability in a percent change
within a very small range, qualitatively the trends are similar in
Figure 2B as compared to Figure 2A.
QUANTIFICATION OF CPI-17 PHOSPHORYLATION
One of the primary mechanisms by which PKC activates or
enhances contraction of smooth muscle is via phosphorylation of
CPI-17 (Eto et al., 1997,2004). PhosphorylatedCPI-17binds to the
38-kDa catalytic subunit of the MLC phosphatase which inhibits
its activity (Eto et al., 1995; Ito et al., 2004). We have recently
shown that carbachol-induced activation of bladder smoothmus-
cle increasesCPI-17 phosphorylation and this increase is abolished
by Bis and is signiﬁcantly reduced by H-1152 (Wang et al., 2009).
Therefore, we were interested in determining if activation of blad-
der smoothmuscle by PKC alone produced a different sequence of
signaling events in terms of PKC and ROCK activity as compared
to the numerous signaling pathways activated by carbachol. The
ﬁrst series of experiments to address this questionwere designed to
measure CPI-17 phosphorylation levels during PDBu stimulation
in the presence or absence of Bis. Figure 3A shows a represen-
tative Western blot of total and phospho-CPI-17 antibody and
Figure 3B shows the averaged results of four to eight blots. Lev-
els of Thr38-phospho-CPI-17 were signiﬁcantly increased at all
time points measured during PDBu stimulation. Inhibition of
PKC with Bis abolished the PDBu-dependent increase in CPI-17
phosphorylation. Inhibition of ROCK with H-1152 delayed the
onset of CPI-17 phosphorylation levels but did not affect themax-
imal levels attained during the later phases of PDBu stimulation.
As expected, these results suggest that CPI-17 phosphorylation
is increased by activation of PKC. Moreover, activation of PKC
with PDBu also results in ROCK-dependent increases in CPI-17
phosphorylation, at least during the initial phase of a contraction.
A second set of experimentswere performed tomeasureCPI-17
phosphorylation levels in response 300μM DOG. These experi-
ments were performed to provide results using two activators of
PKC; the chemical activator PDBu and the analog of the physi-
ological activator DOG. If both PKC activators produce similar
results, then this would provide additional support to the assump-
tion that PDBu activates PKC and that our results reﬂect events
that occur during normal physiological stimulation. As shown
in Figures 3C,D, Thr38-phospho-CPI-17 levels were signiﬁcantly
increased at 2.5 and 5min of DOG stimulation. Phosphorylation
levels were not signiﬁcantly different from control values at 10min
of stimulation with DOG or at any time point after the addition
of vehicle alone (DMSO, only 5min is shown). Similar to the
ﬁnding that the development of force in response to DOG was
slower as compared to PDBu-dependent force development, the
increase in CPI-17 phosphorylation levels was also slower. CPI-17
phosphorylation levels qualitatively paralleled the increase in force
FIGURE 3 | RepresentativeWestern blots and quantification of
Thr38-CPI-17 phosphorylation levels from bladder smooth muscle
contracted with PDBu or DOG. (A) RepresentativeWestern blots of strips
stimulated with PDBu (3μM) in the presence or absence of Bis (3μM) or
H-1152 (1μM). (B) Quantitative results of four to eight blots such as that
shown in (A). PDBu stimulation signiﬁcantly increased
phospho-Thr38-CPI-17 levels at all time points (black bars). Inhibition of PKC
with Bis (light gray bars) abolished increases in CPI-17 phosphorylation
levels at all time points. Inhibition of ROCK with H-1152 (dark gray bars)
signiﬁcantly reduced CPI-17 phosphorylation levels only at 1.5min. (C)
RepresentativeWestern blots of bladder smooth muscle strips stimulated
with DOG (300μM) or vehicle (DMSO) alone. (D) Quantitative results of
four to eight blots such as that shown in (C). DOG stimulation signiﬁcantly
increased phospho-Thr38-CPI-17 levels at 2.5 and 5min of stimulation.
Values shown are the means±SE of four to eight determinations.
#P <0.05, compared with values at 0min or control. *P <0.05, compared
with values in response to PDBu at the same time point.
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developed in response to both PDBu and DOG (Figures 1B,C as
compared to Figures 3B,D).
QUANTIFICATION OF MYPT1 PHOSPHORYLATION
ROCK-catalyzed phosphorylation of MYPT1 has been shown to
be one of the major mechanisms regulating MLC phosphatase
activity (Hartshorne, 1998). Carbachol stimulation of bladder
smooth muscle increases Thr850-MYPT1 phosphorylation but
not Thr696-MYPT1 phosphorylation (Wang et al., 2009). In the
present study, we used PDBu stimulation to address the potential
role of PKC in ROCK-catalyzed phosphorylation of MYPT1 at
either Thr696 or Thr850 and DOG stimulation to examine ROCK-
catalyzed phospho-Thr850-MYPT1. We were also interested in
conﬁrming our previous observation that a constitutively active
ROCK which phosphorylates Thr850-MYPT1 is functional in
resting, unstimulated bladder smooth muscle (Wang et al., 2009).
Figure 4A shows a representative Western blot of PDBu-
stimulated phosopho-Thr696-MYPT1 and Figure 4B shows the
averaged data of 8–12 blots. Stimulation of bladder smooth mus-
cle with PDBu neither increased nor decreased phosphorylation
levels of Thr696-MYPT1. Additionally, neither Bis nor H-1152 had
any effect on Thr696-MYPT1 levels at rest or following PDBu
stimulation.
Figure 5A shows a representative Western blot of PDBu-
stimulated phospho-Thr850-MYPT1 and Figure 5B shows the
averaged data of 9–11 blots. Stimulation of bladder smoothmuscle
FIGURE 4 | RepresentativeWestern blot and quantification of
phospho-Thr696-MYPT1 levels from bladder smooth muscle contracted
with PDBu in the presence or absence of Bis or H-1152.
(A) RepresentativeWestern blots of strips stimulated with PDBu (3μM) in
the presence of either Bis (3μM) or H-1152 (1μM). (B) Averaged results of
8–12 experiments of the type shown in (A). PDBu stimulation alone did not
increase phospho-Thr696-MYPT1 levels (black bars). Inhibition of either PKC
(light gray bars) or ROCK (dark gray bars) had no effect on
phospho-Thr696-MYPT1 levels in all strips. Values shown are the means±SE
of 8–12 determinations.
FIGURE 5 | RepresentativeWestern blot and quantification of
phospho-Thr850-MYPT1 levels from bladder smooth contracted with
PDBu or DOG. (A) RepresentativeWestern blots of strips stimulated with
PDBu (3μM) in the presence or absence of either Bis (3μM) or H-1152
(1μM). (B) Averaged results of 9–11 experiments of the type shown in (A).
PDBu stimulation alone did not increase phospho-Thr850-MYPT1 levels
(black bars). Inhibition of PKC by Bis (light gray bars) did not affect
phospho-Thr850-MYPT1 levels at any time point. Inhibition of ROCK (dark
gray bars) signiﬁcantly decreased phospho-Thr850-MYPT1 levels at all time
points measured including basal values. (C) RepresentativeWestern blot of
strips stimulated with DOG (300μM). (D) Averaged results of 9–11
experiments of the type shown in (C). Similar to the results with PDBu,
DOG stimulation did not increase phospho-Thr850-MYPT1 levels at any time
point measured. Values shown are the means±SE of 9–11 determinations.
*P <0.05, compared with values in strips contracted with PDBu at the
same time points.
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with PDBu had no effect on Thr850-MYPT1 phosphorylation lev-
els. Consistent with the lack of effect of PDBu on Thr850-MYPT1
phosphorylation, inhibition of PKC with Bis during PDBu stim-
ulation was also without effect. In contrast to the lack of effect
of ROCK inhibition on basal levels of phospho-Thr696-MYPT1,
inhibition of ROCK with H-1152 (added 20min prior to “0”
time point) signiﬁcantly inhibited basal levels as well as levels at
all other timed measurements of phospho-Thr850-MYPT1. These
results suggest that PKC is not involved in the activation of either
the constitutively active ROCK or the ROCK that phosphorylates
Thr850-MYPT1 during agonist activation.
Figures 5C,D shows the results of 300μM DOG on phospho-
Thr850-MYPT1 levels. DOG stimulation of bladder smooth mus-
cle did not produce any increase in phospho-Thr850-MYPT1 lev-
els as compared to control values. These results further validate
the hypothesis that PKC is not involved in activation of ROCK-
catalyzedMYPT1 phosphorylation in bladder smooth muscle and
that both PDBu and DOG act via similar pathways.
DISCUSSION
We recently presented results aimed at understanding the signaling
steps involved in carbachol-induced activation of bladder smooth
muscle contraction (Wang et al., 2009). Carbachol stimulation of
bladder smooth muscle activates both PKC and ROCK signaling
pathways. As such, using carbachol alone, it is difﬁcult to assess the
speciﬁc role(s) for either PKC or ROCK. Therefore, in this present
study we used PDBu and DOG as contractile activators as they
are presumed to only activate PKC (Castagna et al., 1982). Any
activity consistent with a role for ROCK therefore should be due
to activation by PKC or a downstream PKC-dependent mediator.
Therefore, using this approach with PDBu and DOG as the stim-
uli should allow us to dissect which step(s) in the initiation of a
contraction is the result of PKC, ROCK, or both.
Themajor novel ﬁndings in this study are: (1) PDBu andDOG-
induced contraction of bladder smoothmuscle involves activation
of PKC directly as well as PKC-dependent activation of ROCK; (2)
Consistent with results using vascular smooth muscle (Fulginiti
et al., 1993), PDBu-dependent force is not strictly dependent on
increased levels of MLC phosphorylation; (3) CPI-17 is phos-
phorylated directly by PKC and also by PKC-dependent activated
ROCK; (4) Although ROCK activation is involved in PDBu and
DOG-dependent contractions, phosphorylation of MYPT1 is not;
and (5) We conﬁrmed the previously submitted hypothesis that
bladder smooth muscle contains a constitutively active isoform of
ROCK (Poley et al., 2008;Wang et al., 2009). Our ﬁndings coupled
with our previous study using carbachol as the contractile stimu-
lus (Wang et al., 2009) have led to the development of a working
model for rabbit bladder smooth muscle contraction (shown in
Figure 6).
PDBu VERSUS CARBACHOL-INDUCED FORCE AND MLC
PHOSPHORYLATION: ROLE(S) OF PKC AND ROCK
The mechanism by which PDBu produces contraction of smooth
muscle is unclear. A previous report from our laboratory
showed that PDBu induces calcium and MLC phosphorylation-
independent contraction of vascular smooth muscle (Fulginiti
et al., 1993). In contrast others have observed that PDBu-induced
FIGURE 6 | Proposed model for the regulation of bladder smooth
muscle contraction. Carbachol stimulation of bladder smooth muscle
results in the IP3 dependent release of Ca2+ and MLC kinase-catalyzed
phosphorylation of the MLC. Additionally, both PKC and ROCK are
activated. PKC directly catalyzes the phosphorylation of CPI-17 while ROCK
catalyzes CPI-17 phosphorylation via its activation by PKC. The result is
inhibition of the MLC phosphatase and an increase in force. ROCK also
catalyzes the phosphorylation of Thr850-MYPT1; however, this is either via a
different isoform or pool of ROCK than that which phosphorylates CPI-17. A
constitutively active pool of ROCK is present in bladder smooth muscle and
is proposed to be responsible for the high basal phosphorylation values of
Thr850-MYPT1 due to its inhibition of the MLC phosphatase. PLC,
phospholipase C; DAG, diacylglycerol; Rho GEF, Rho guanine nucleotide
exchange factor; MLCP, MLC phosphatase; MLCK, MLC kinase; CaM,
calmodulin.
vascular smoothmuscle and iris sphincter contractions are at least
partly dependent on an increase in intracellular Ca2+ and MLC
phosphorylation (Howe and Abdel-Latif, 1987; Singer and Baker,
1987). The apparent discrepancy could be due to the existence of
various PKC isoforms in different smooth muscles and species. In
our present study, we investigated the mechanism by which PKC
induces contraction in bladder smoothmuscle, in part, bymeasur-
ing PDBu as compared to carbachol-dependent increases in MLC
phosphorylation.
PDBu stimulation causes a small but signiﬁcant increase in
MLC phosphorylation, which is decreased by inhibition of either
PKC or ROCK. Carbachol stimulation produces a robust contrac-
tion similar in magnitude to that produced by KCl (Wang et al.,
2009). PDBu stimulation, in contrast to carbachol, produces a
smaller contraction. Removal of extracellular calcium or deple-
tion of all sources of calcium prevented contraction in response
to PDBu, demonstrating the calcium-dependence, and speciﬁcally
the extracellular calcium-dependence of the contraction. Thismay
be due to inactivation of theMLC kinase in the absence of calcium
or the isoform of PKC activated by PDBu resulting in contraction
is from the calcium-dependent PKC family. Additionally, stimu-
lation with the inactive phorbol ester, α-PDBu, did not produce
a contraction in bladder smooth muscle. This suggests that the
increase in force in response toPDBuwasnot simplyphorbol ester-
dependent but involved activation of downstream signaling path-
ways speciﬁc to PDBu stimulation, speciﬁcally PKC-dependent
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pathways. This ﬁnding coupled with the fact that DOG, a 1,2-
diacylgycerol analog, also induced a contraction qualitatively sim-
ilar to that of PDBu supports the conclusion that PKC is the
downstream effector. The patterns of force development andMLC
phosphorylation in both carbachol and PDBu-dependent con-
tractions are similar; such that in both cases an early increase
in force is followed by a decrease to basal or near basal values.
Not surprising, PDBu-dependent increases in both MLC phos-
phorylation and force were abolished by Bis. However, Bis only
affected the carbachol-dependent increase in MLC phosphory-
lation, and reduced but did not abolish the carbachol-induced
increase in force (Wang et al., 2009). This suggests that a carbachol-
dependent, but PKC andMLCphosphorylation-independent con-
tractile pathway, is present in bladder smoothmuscle. These results
are inconsistent with an earlier study using lower urinary tract
smooth muscle which suggested that PDBu-induced contractions
may be only partially mediated by PKC (Yoshida et al., 1992). This
discrepancy may be due, in part, to the use of PKC inhibitors with
different speciﬁcities as the earlier report used H-7.
The conﬂicting results in the literature raise the potential lim-
itation inherent in all pharmacological investigations, reliance on
the speciﬁcity of the chosen inhibitor. These limitations are nicely
discussed in work from Cohen’s laboratory (Davies et al., 2000;
Bain et al., 2007). In our present study we used Bis for inhibition
of PKC and H-1152 for inhibition of ROCK. The inhibitors and
concentrations of the inhibitors usedwere based on the results pre-
sented in a previous study from our laboratory (Wang et al., 2009).
Speciﬁcally, we were interested in directly comparing our current
results using PDBu or DOGwith the results using carbachol stim-
ulation in our earlier report (Wang et al., 2009). As discussed by
Cohen’s group (Davies et al., 2000; Bain et al., 2007), Bis and H-
1152, at concentrations used in our study, exhibit non-selective
activity against kinases in addition to PKC and ROCK. These stud-
ies were preformed in biochemical assays and cells as compared to
our present results using tissues which have signiﬁcantly different
responses to both activators and inhibitors of kinases. Moreover,
we have found that neither 3μM Bis nor 1μM H-1152 inhibited
Ca2+-dependent contractions in Triton X-100 skinned or α-toxin
permeabilized preparations of bladder smooth muscle (data not
shown). This suggests that, at a minimum, the MLC kinase is not
inhibited by either Bis or H-1152 at the concentrations used in
our current study. Therefore, given this information coupled with
the fact that the present study was designed to extend and com-
plement our previous ﬁndings (Wang et al., 2009), we believe the
use of these inhibitors is appropriate if interpretations are made
cautiously.
PDBu VERSUS CARBACHOL-INDUCED CPI-17 PHOSPHORYLATION:
ROLE(S) OF PKC AND ROCK
The fact that PDBu-induced contractions are signiﬁcantly
decreased by a ROCK inhibitor suggests that PKC activates ROCK
in bladder smooth muscle (Figure 1). Activation of ROCK by
PKC, especially the PKCδ isoform, has been shown to be involved
in several cell functions, such as vascular smooth muscle migra-
tion and contraction (Kandabashi et al., 2003; Ohtsu et al., 2005;
Poole and Furness, 2007).Our laboratory demonstrated that PKCδ
and most other novel and classic isoforms of PKC are present in
rabbit bladder smooth muscle (unpublished results). Our ﬁnd-
ing that ROCK inhibition abolishes PDBu-dependent increases in
MLCphosphorylationbut only partially reduces PDBu-dependent
increases in force, suggests a direct role for PKC in addition to
an indirect role via ROCK activation in bladder smooth muscle
contraction.
Our previous study showed that agonist stimulation of bladder
smooth muscle signiﬁcantly increased Thr38-CPI-17 phosphory-
lation (Wang et al., 2009),whichwas primarily caused by PKCdur-
ing both the phasic and tonic-like phases of contraction. ROCK,
however, was also involved in CPI-17 phosphorylation but only
during the later tonic-like phase of contraction. PDBu stimula-
tion also increased Thr38-CPI-17 phosphorylation by activation
of PKC, which is conﬁrmed by the fact that the PKC inhibitor Bis
abolished CPI-17 phosphorylation. Stimulation with DOG also
increased Thr38-CPI-17 phosphorylation. Because diacylglycerols
are activators of PKC these results support the hypothesis that
any increase in CPI-17 phosphorylation is due to activation of
PKC. Inhibition of ROCK also decreased CPI-17 phosphoryla-
tion. However, in contrast to our study using carbachol as the
stimulus which provided a role for ROCK-catalyzed CPI-17 phos-
phorylation in the later phase of contraction, our present results
provide a role for ROCK-catalyzed CPI-17 phosphorylation only
during the early phase of the PDBu-induced contraction. This sug-
gests that carbachol and PDBu induce the activation of different
isoforms of ROCK and/or induce different temporal proﬁles of
ROCK activation.
PDBu VERSUS CARBACHOL-INDUCED MYPT1 PHOSPHORYLATION:
ROLE(S) OF PKC AND ROCK
MYPT1 is the regulatory subunit of theMLC phosphatase holoen-
zyme. Our laboratory found that in bladder smooth muscle,
Thr850-MYPT1but not Thr696-MYPT1phosphorylation increases
during agonist stimulation (Wang et al., 2009). Unstimulated
resting tissues exhibit signiﬁcant levels of both Thr696 and Thr850-
MYPT1 phosphorylation. Basal phosphorylation levels of Thr850-
MYPT1 are sensitive to ROCK inhibition while basal phosphory-
lation of Thr696-MYPT1 is not. In the present study, we activated
only the PKCpathway in bladder smoothmuscle by the addition of
PDBu orDOGand observed the effect of PKC and potentially PKC
activated ROCK on the phosphorylation of MYPT1. Our results
demonstrate that neither Thr696 nor Thr850-MYPT1 phosphory-
lation are signiﬁcantly increased during PDBu or DOG-induced
contraction. These results suggest that although Thr850-MYPT1
is apparently involved in the sustained phase of a carbachol-
stimulated contraction, it is not important in a PKC-induced
contraction and it is not phosphorylated by the pool of ROCK
activated by the PKC pathway.
Consistentwith our previous report (Wang et al., 2009),Thr850-
MYPT1 phosphorylation is important in the maintenance of rest-
ing basal tone of bladder smooth muscle as we demonstrated that
inhibition of ROCK decreased both Thr850-MYPT1 phosphory-
lation and resting levels of force. This conclusion is consistent
with work showing that phosphorylated MYPT1 is highly resis-
tant to dephosphorylation, such that this mechanism allows for
the long-term regulation of force rather than the acute agonist-
stimulated contraction (Takizawa et al., 2002b). Also consistent
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with our previous ﬁnding, basal Thr850-MYPT1 phosphorylation
is sensitive to ROCK inhibition.We proposed that a constitutively
active pool of ROCK, which phosphorylates only Thr850-MYPT1
at rest, is present in bladder smooth muscle. Our proposal is con-
sistent with work from Poley et al. (2008) who also suggested the
existence of a constitutively active pool of ROCK which may con-
tribute to contraction in response to the quick-stretch of bladder
smooth muscle.
Several kinases other than ROCK have been proposed to phos-
phorylate Thr696-MYPT1 in vitro and in vivo, such as ZIP-like
kinase, integrin-linked kinase,myotonic dystrophy protein kinase,
p21-activated protein kinase, and Raf-1 (Woodsome et al., 2001;
Takizawa et al., 2002a; Velasco et al., 2002; Wilson et al., 2005). It
is unknown to date which kinase phosphorylates Thr696-MYPT1
in the resting state in bladder smooth muscle, although the lack of
effect of H-1152 would suggest it is not ROCK. High basal levels
of MYPT1 phosphorylation in bladder smooth muscle may con-
tribute to the inactivation of MLC phosphatase resulting in a high
resting tone in the bladder wall. Normally as the bladder ﬁlls the
low compliance of the bladder wall allows for the maintenance of
a low pressure while the volume of the bladder increases. If the
bladder smooth muscle has an elevated level of MYPT1 phospho-
rylation and therefore MLC phosphorylation, the compliance of
the bladder wall will be decreased resulting in an increase in blad-
der pressure with ﬁlling. Therefore, any pathophysiological state
that resulted in an increase inMYPT1 phosphorylation could have
dramatic effects on ﬁlling pressure. The phenomenon of high rest-
ing MYPT1 phosphorylation and possibly high resting tension is
not speciﬁc to bladder smooth muscle as Niiro et al. (2003) found
a signiﬁcant level of basal Thr641 (Rat sequence, equals Thr696 in
chicken sequence) phosphorylation in rabbit femoral artery.
One of the more interesting ﬁndings in this study is the differ-
ential effect of ROCK inhibition, with H-1152, on CPI-17 phos-
phorylation as compared to MYPT1 phosphorylation (Figure 3
versus 4 and 5). Based on the inhibitory effects of H-1152 on
PDBu-induced increases in CPI-17 phosphorylation, the logical
assumption is that PDBu-induced activation of PKC results in acti-
vation of ROCK which in turn phosphorylates CPI-17. However,
stimulation with PDBu alone does not produce any increase in
phosphorylation of the known substrate for ROCK,MYPT1. This
would suggest that either PKC activates an isoform of ROCK that
does not phosphorylate MYPT1 or PKC activates a speciﬁc pool
or compartment of ROCK that is speciﬁc to CPI-17. An alternate
explanation is that there is a non-speciﬁc effect of H-1152 on PKC
or a downstream substrate of PKC.
Our study proposes an important role for the so-called Ca2+
sensitizers,MYPT1 and CPI-17, in contraction of bladder smooth
muscle.A recent report fromKamm’s laboratory (Ding et al., 2009)
would suggest that these proteins may only be important in the
slower contraction induced by carbachol as compared to electrical
ﬁeld stimulation or during the later phase of a contractile event.
They demonstrated that in the very early phase of mouse bladder
smooth muscle contraction, there was a rapid, millisecond time-
frame increase in cellular Ca2+ and levels ofMLCphosphorylation
without any evidence of increases in CPI-17 or MYPT1 phospho-
rylation. It is possible that this is also the case at time points earlier
than thosemeasured in our current study. Our results do, however,
suggest that both CPI-17 andMYPT1 phosphorylation are impor-
tant in the later phase of a rabbit bladder contraction. Consistent
with our ﬁndings that both PKC and ROCK play an important
role in a bladder contraction on the time-frame of minutes is that
inhibitors of either PKCor ROCKhad a greater effect on the tonic-
like as compared to the initial phasic part of contraction of guinea
pig bladder smooth muscle (Roosen et al., 2009). Thus, it appears
plausible that the very early increase in force in the bladder wall is
dependent on Ca2+ and MLC phosphorylation whereas the peak
development of force and the more tonic-like phase rely more on
PKC and ROCK activation and therefore the Ca2+ sensitization
pathway.
In summary, we propose the model shown in Figure 6 for the
regulation of bladder smooth muscle contraction. Agonist activa-
tion of bladder smooth muscle involves both PKC and ROCK sig-
nalingpathways in thedevelopment andmaintenance of a contrac-
tion. CPI-17 is amajor downstream regulator of PKC both directly
and indirectly via activation of ROCK. Whether the ROCK acti-
vated by PKC resulting in the phosphorylation of CPI-17 is a dif-
ferent ROCK isoform or from a different pool of ROCK than that
important in catalyzing MYPT1 phosphorylation is not known.
Althoughnot directly tested in our studies,but basedon a vast liter-
ature,CPI-17 phosphorylation results in the inhibition of theMLC
phosphatase and an increase in force development. Thr850-MYPT1
is phosphorylated by ROCK during agonist stimulation and
inhibitsMLCphosphatase activity, but that ROCK isoformor pool
is not part of the PKC–ROCK signaling pathway. At rest, a consti-
tutively active pool of ROCK phosphorylates Thr850-MYPT1 and
an unknown kinase(s) phosphorylates Thr696-MYPT1. Addition-
ally, there are temporal components to the regulation of ROCK
such that PKC activated ROCK is important in the early phase of a
bladder smooth muscle contraction while direct ROCK activation
via agonist stimulation plays a larger role in the later phase of a
contraction. Thus,bladder smoothmuscle contraction is regulated
by a complex interaction of several signaling pathways exhibiting
both cross-activation and temporal components.
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